Department of Physiology and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61. doi: 10.1038/nrd3738.
Although the increased lifespan of our populations illustrates the success of modern medicine, the risk of developing many diseases increases exponentially with old age. Caloric restriction is known to retard ageing and delay functional decline as well as the onset of disease in most organisms. Studies have implicated the sirtuins (SIRT1-SIRT7) as mediators of key effects of caloric restriction during ageing. Two unrelated molecules that have been shown to increase SIRT1 activity in some settings, resveratrol and SRT1720, are excellent protectors against metabolic stress in mammals, making SIRT1 a potentially appealing target for therapeutic interventions. This Review covers the current status and controversies surrounding the potential of sirtuins as novel pharmacological targets, with a focus on SIRT1.
虽然我们的人口寿命延长表明了现代医学的成功,但随着年龄的增长,许多疾病的发病风险呈指数级增长。众所周知,热量限制可以延缓衰老和功能下降,以及大多数生物体疾病的发生。研究表明,sirtuins(SIRT1-SIRT7)是热量限制在衰老过程中对关键作用的介导者。有两种不相关的分子,白藜芦醇和 SRT1720,在某些情况下已被证明能增加 SIRT1 的活性,它们是哺乳动物代谢应激的极好保护剂,这使得 SIRT1 成为治疗干预的一个有吸引力的潜在靶点。这篇综述涵盖了 sirtuins 作为新型药理学靶点的现状和争议,重点是 SIRT1。